August 15, 2013

Boehringer Ingelheim, a research-based, global pharmaceutical company, today announced a multi-year agreement with Brigham and Women's Hospital on a long-term study program to assess comparative effectiveness and safety, as well as prescribing patterns, of oral anticoagulants, including Pradaxa, for the reduction of stroke risk in U.S. patients with non-valvular atrial fibrillation.

October 19, 2010

The Food and Drug Administration approved a drug for preventing strokes and blood clots in...

September 20, 2010

A Food and Drug Administration advisory committee has recommended approval of a drug for patients...

July 6, 2010

Launch and use of new heart drugs will drive the market for drugs to treat...